Topic:

Venture Capital

Latest Headlines

Latest Headlines

Cambrian raises $10M for DNA printing tech used by GSK

Proponents of DNA printing have heralded it as a way to do everything from bringing alien life back from Mars to delivering vaccines in the event of a pandemic. And the technology has attracted GlaxoSmithKline and Roche, both of which have taken an interest in Cambrian Genomics.

Novartis VC unit co-leads $53M investment in BioNano Genomics

BioNano Genomics has restocked its coffers to fund an assault on the genome analysis sector. The San Diego, CA-based genome mapping firm raised a $53 million war chest from Novartis' venture fund and other investors to accelerate uptake of its Irys DNA analysis device and accompanying software.

BioNano bags $53M to dig deeper into genomics with Novartis on board

San Diego's BioNano Genomics has raised a $53 million C round to bankroll its efforts to decode the so-called inaccessible genome, adding Novartis to its investor syndicate as it works to amplify its profile.

U.K. heavyweight Woodford gambles $25M on controversial brain cancer vaccine

U.K. biotech investment heavyweight Neil Woodford has invested $25 million in the U.S. biotech Northwest Biotherapeutics, gambling that its controversial Phase III study on a new therapeutic vaccine for brain cancer comes up a winner.

Juno takes its hot CAR-T cancer tech to Wall Street in $150M IPO

In what will likely be the most closely watched IPO in biotech, Juno Therapeutics has rolled out a $150 million offering that is likely to make a big splash on the market.

Blueprint Medicines banks $50M for its personalized take on cancer

Third Rock Ventures startup Blueprint Medicines has hauled in a $50 million C round, cash that'll see its way through clinical trials and keep its promising platform generating new candidates.

Fledgling Ziarco grabs a $33M transatlantic round for PhII atopic dermatitis drug

Two years after Michael Yeadon and a close-knit group of Pfizer investigators managed to grab some of the pharma giant's anti-inflammatory assets on the way out the door at Sandwich, they've drummed up a $33 million B round for their biotech from some U.S. and European investors. And now they're set to launch a midstage clinical program to help determine the value of what they took with them when launching Ziarco.

Trevi wraps up a $26M round to fund its anti-itching drug

New Haven, CT's Trevi Therapeutics banked another $11 million in venture cash, bringing its B round to $26 million and giving it the cash it needs to complete a pivotal trial for its top prospect.

Tolero wraps up a $22.4M round to support its cancer contender

Tolero Pharmaceuticals has pocketed a second tranche of its Series B funding round, netting $22.4 million in total as it prepares to take its expirimental marrow cancer treatment into late-stage development.

Novo Nordisk pushes back date of IT IPO decision to 2015

Having spent the past 10 months weighing up the merits of a separate listing for its IT subsidiary NNIT, Novo Nordisk has decided it needs to wait a little longer before pulling the trigger.